-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Bright Minds Biosciences, Maintains $147 Price Target

Benzinga·02/17/2026 11:00:56
Listen to the news
BTIG analyst Thomas Shrader maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.